Page 132 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

130 CHAPTER 5 Cell therapy

[40] A.J. Giles, C.M. Reid, J.D. Evans, M. Murgai, Y. Vicioso, S.L. Highfill, et al. Acti-
vation of hematopoietic stem/progenitor cells promotes immunosuppression within the
pre–metastatic niche, Cancer Res. 76 (6) (2016) 1335–1347.
[41] E. Gschweng, S. De Oliveira, D.B. Kohn, Hematopoietic stem cells for cancer immuno-
therapy, Immunol. Rev. 257 (1) (2014) 237–249.
[42] P. Sachamitr, S. Hackett, P.J. Fairchild, Induced pluripotent stem cells: challenges and
opportunities for cancer immunotherapy, Front. Immunol. 5 (2014) 176.
[43] Z. Jiang, Y. Han, X. Cao, Induced pluripotent stem cell (iPSCs) and their application in
immunotherapy, Cell. Mol. Immunol. 11 (1) (2014) 17.
[44] F. Rami, H. Mollainezhad, M. Salehi, Induced pluripotent stem cell as a new source for
cancer immunotherapy, Genet. Res. Int. (2016) 2016.
[45] Patel M. and S. 6, no. 3, pp. 367–380, 2010.
[46] H. Wakao, K. Yoshikiyo, U. Koshimizu, T. Furukawa, K. Enomoto, T. Matsunaga, et al.
Expansion of functional human mucosal-associated invariant T cells via reprogramming
to pluripotency and redifferentiation, Cell Stem Cell 12 (5) (2013) 546–558.